Patents by Inventor Iain THOMPSON

Iain THOMPSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED CAS9 PROTEIN, AND USE THEREOF
    Publication number: 20230279374
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Application
    Filed: November 25, 2022
    Publication date: September 7, 2023
    Applicants: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu NUREKI, Hiroshi NISHIMASU, Hisato HIRANO, Shohei KAJIMOTO, Tetsuya YAMAGATA, Yuanbo QIN, Keith M. CONNOLLY, Iain THOMPSON
  • Modified CAS9 protein, and use thereof
    Patent number: 11530396
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: December 20, 2022
    Assignees: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu Nureki, Hiroshi Nishimasu, Hisato Hirano, Shohei Kajimoto, Tetsuya Yamagata, Yuanbo Qin, Keith M. Connolly, Iain Thompson
  • MODIFIED CAS9 PROTEIN, AND USE THEREOF
    Publication number: 20210163907
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Application
    Filed: September 5, 2018
    Publication date: June 3, 2021
    Applicants: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu NUREKI, Hiroshi NISHIMASU, Hisato HIRANO, Shohei KAJIMOTO, Tetsuya YAMAGATA, Yuanbo QIN, Keith M. CONNOLLY, Iain THOMPSON